Amneal announced FDA acceptance of its Biologics License Application (BLA) for two proposed denosumab biosimilars ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution ...

The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Looking ahead, revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.5% growth forecast ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

Teva Pharmaceutical Industries Ltd. failed to convince the Federal Circuit to reconsider a December ruling that five patents ...

Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The ...

Learn more about whether Amneal Pharmaceuticals, Inc. or HUTCHMED (China) Limited is a better investment based on AAII's A+ ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Executive Officer and President ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.